Role of Artificial Intelligence in Simulation and Therapeutics in Neurodegenerative Diseases

Year : 2026 | Volume : 16 | Issue : 01 | Page : 19 29
    By

    Tulika Chaturvedi,

  • Shalini Mani,

  1. Researcher, Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India
  2. Associate Professor, Department of Biotechnology, Jaypee Institute of Information Technology, A 10, Block A, Industrial Area, Sector 62, Noida, Uttar Pradesh, India

Abstract

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, etc., are a cause of significant mortality rates due to a lack of curative treatments and their complex nature. Traditional therapeutic methodologies have several disadvantages such as slow diagnosis and a lack of effective treatments. They mainly focused on the management of the disease rather than curing it. The integration of artificial intelligence in the simulation and therapeutics of neurodegenerative diseases has offered a revolutionary explication. Artificial intelligence models provide early diagnosis, accurate disease modeling, and optimized drug development. Machine learning and deep learning are subsets of artificial intelligence that examine massive datasets from biomarkers, genomics, and neuroimaging to recognize trends in disease progression and suggest personalized treatments. Diagnosis precision can be elevated by agent-based modeling, predictive modeling, and image analysis. In therapeutics, artificial intelligence aids in drug repurposing, de novo drug development, personalized medicine, and the development of nanomedicine to overcome the challenge of crossing the blood–brain barrier. Artificial intelligence facilitates the development of personalized medicine by altering the treatments according to the patient’s genomic clinical data, enhancing the effectiveness and minimizing the aftereffects. Irrespective of these advancements, challenges, like data quality, model understandability, and regulatory barriers, still exist. To enable the widespread application of artificial intelligence, these challenges should be addressed. Due to its ability to perform real-time diagnosis, biomarker supervision, and clinical trials, Artificial Intelligence has an optimistic future in the simulation and therapeutics of neurodegenerative diseases. Artificial intelligence can transform the healthcare industry by delivering more accurate, accessible, and reliable therapies that will optimize patient outcomes and quality of life. This article reviews various artificial intelligence tools that are used in the therapeutics and simulation of neurodegenerative disorders.

Keywords: Artificial intelligence, biomarkers, blood–brain barrier, clinical trials, deep learning, imaging, machine learning, nanomedicine, neurodegenerative diseases, personalized medicine

[This article belongs to Research and Reviews: A Journal of Neuroscience ]

How to cite this article:
Tulika Chaturvedi, Shalini Mani. Role of Artificial Intelligence in Simulation and Therapeutics in Neurodegenerative Diseases. Research and Reviews: A Journal of Neuroscience. 2026; 16(01):19-29.
How to cite this URL:
Tulika Chaturvedi, Shalini Mani. Role of Artificial Intelligence in Simulation and Therapeutics in Neurodegenerative Diseases. Research and Reviews: A Journal of Neuroscience. 2026; 16(01):19-29. Available from: https://journals.stmjournals.com/rrjons/article=2026/view=240672


References

  1. Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693–714.
  2. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90.
  3. Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, et al. The neuropsychiatry of Parkinson’s disease: Advances and challenges. Lancet Neurol. 2022;21(1):89–102.
  4. McColgan P, Thobhani A, Boak L, Schobel SA, Nicotra A, Palermo G, et al. Tominersen in adults with manifest Huntington’s disease. N Engl J Med. 2023;389(23):2203–5.
  5. Zhang Q, Li T, Xu M, Islam B, Wang J. Application of optogenetics in neurodegenerative diseases. Cell Mol Neurobiol. 2024;44(1):57.
  6. Palaniyappan R, Arthanari S, Subramanian M, Periyasamy P, Pethappachetty P, Ganesan R, et al. Nanotechnology-driven approaches in overcoming drug delivery challenges for neurodegenerative diseases. Indian J Pharm Educ Res. 2024;58(4S):S1185–200.
  7. Secinaro S, Calandra D, Secinaro A, Muthurangu V, Biancone P. The role of artificial intelligence in healthcare: A structured literature review. BMC Med Inform Decis Mak. 2021;21:1–23.
  8. Hussain I, Nazir MB. Empowering healthcare: AI, ML, and deep learning innovations for brain and heart health. Int J Adv Eng Technol Innov. 2024;1(4):167–88.
  9. Zheng K, Shen Z, Chen Z, Che C, Zhu H. Application of AI-empowered scenario-based simulation teaching mode in cardiovascular disease education. BMC Med Educ. 2024;24(1):1003.
  10. Kothinti RR. Deep learning in healthcare: Transforming disease diagnosis, personalized treatment, and clinical decision-making through AI-driven innovations. World J Adv Res Rev. 2024;24(2):2841–56.
  11. Abbas MK, Rassam A, Karamshahi F, Abunora R, Abouseada M. The role of AI in drug discovery. ChemBioChem. 2024;25(14):e202300816.
  12. Iftikhar M, Saqib M, Zareen M, Mumtaz H. Artificial intelligence: Revolutionizing robotic surgery. Ann Med Surg. 2024;86(9):5401–9.
  13. Rehan H. Enhancing early detection and management of chronic diseases with AI-driven predictive analytics on healthcare cloud platforms. J AI-Assist Sci Discov. 2024;4(2):1–38.
  14. Vidyarthi A. Monitoring and diagnosis of neurodegenerative diseases through advanced sensor integration and machine learning techniques. Int J Eng Artif Intell Manag Decis Support Policies. 2024;1(2):33–41.
  15. Shen Y, Zhao X, Wang K, Sun Y, Zhang X, Wang C, et al. Exploring white matter abnormalities in young children with autism spectrum disorder: Integrating multi-shell diffusion data and machine learning analysis. Acad Radiol. 2024;31(5):2074–84.
  16. Hata M, Miyazaki Y, Mori K, Yoshiyama K, Akamine S, Kanemoto H, et al. Utilizing portable electroencephalography to screen for pathology of Alzheimer’s disease: A methodological advancement in diagnosis of neurodegenerative diseases. Front Psychiatry. 2024;15:1392158.
  17. Lal U, Chikkankod AV, Longo L. Fractal dimensions and machine learning for detection of Parkinson’s disease in resting-state electroencephalography. Neural Comput Appl. 2024;36(15):8257–80.
  18. Kim M, Song YS, Han K, Bae YJ, Han JW, Kim KW. Impaired glymphatic flow on diffusion tensor MRI as a marker of neurodegeneration in Alzheimer’s disease: Correlation with gray matter volume loss and cognitive decline independent of cerebral amyloid deposition. J Alzheimers Dis. 2024;99(1):279–90.
  19. Gaeta AM, Quijada-López M, Barbé F, Vaca R, Pujol M, Minguez O, et al. Predicting Alzheimer’s disease CSF core biomarkers: A multimodal machine learning approach. Front Aging Neurosci. 2024;16:1369545.
  20. Jan M, Spangaro A, Lenartowicz M, Mattiazzi Usaj M. From pixels to insights: Machine learning and deep learning for bioimage analysis. BioEssays. 2024;46(2):2300114.
  21. Erdaş ÇB, Sümer E. CNN-based neurodegenerative disease classification using QR-represented gait data. Brain Behav. 2024;14(10):e70100.
  22. Li Y, Zeng W, Dong W, Cai L, Wang L, Chen H, et al. MHNet: Multi-view high-order network for diagnosing neurodevelopmental disorders using resting-state fMRI. J Imaging Inform Med. 2025:1–21.
  23. Mukherjee R, Dwivedi R, Jana ND, Chatterjee R, Ghosh S, Dey A, et al. An intelligent CDS (clinical decision support) framework using machine learning algorithms for Parkinson’s disease detection. J Healthc Eng. 2022;2022:1–11.
  24. Kumar GS, Suganya E, Sountharrajan S, Balusamy B, Khadidos AO, Khadidos AO, et al. SRADHO: Statistical reduction approach with deep hyper optimization for disease classification using artificial intelligence. Sci Rep. 2025;15(1):1245.
  25. Barrett MJ, Negida A, Mukhopadhyay N, Kim JK, Nawaz H, Jose J, et al. Optimizing screening for intrastriatal interventions in Huntington’s disease using predictive models. Mov Disord. 2024;39(5):855–62.
  26. Kaliappan S, Ali HM, Maranan R, Sunil G. Mining healthcare data for predictive modeling and prognosis of Alzheimer’s disease progression with artificial intelligence. In: Proc Int Conf Adv Smart Secure Intell Comput (ASSIC). 2024. p.1–7.
  27. Menendez-Gonzalez M. Implementing a tridimensional diagnostic framework for personalized medicine in neurodegenerative diseases. Alzheimers Dement. 2025;21(2):e14591.
  28. Chakraborty C, Bhattacharya M, Lee SS, Wen ZH, Lo YH. The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges. Mol Ther Nucleic Acids. 2024;35(3):102295.
  29. Niazi SK, Magoola M, Mariam Z. Synergistic approaches in neurodegenerative therapeutics: Multi-target drug innovative interventions for Alzheimer’s disease. Pharmaceuticals. 2024;17:741.
  30. Geraci J, Bhargava R, Qorri B, Leonchyk P, Cook D, Cook M, et al. Machine learning hypothesis-generation for patient stratification and target discovery in rare disease: Our experience with open science in ALS. Front Comput Neurosci. 2024;17:1199736.
  31. Zhang YH, Zhao P, Gao HL, Zhong ML, Li JY. Screening targets and therapeutic drugs for Alzheimer’s disease based on deep learning model and molecular docking. J Alzheimers Dis. 2024;100(3):863–78.
  32. Cummings JL, Zhou Y, Van Stone A, Cammann D, Tonegawa-Kuji R, Fonseca J, et al. Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders. Nat Commun. 2025;16(1):1755.
  33. He S, Abarrategi JS, Bediaga H, Arrasate S, González-Díaz H. On additive artificial intelligence discovery of nanoparticle-neurodegenerative disease drug delivery systems. Beilstein Arch. 2024;2024(1):10.
  34. Tong X, Liu X, Tan X, Li X, Jiang J, Xiong Z, et al. Generative models for de novo drug design. J Med Chem. 2021;64(19):14011–27.
  35. González E, Varas P, González-Naranjo P, Ulzurrun E, Pérez C, Páez JA, et al. AI-driven de-novo design and development of non-toxic DYRK1A inhibitors for Alzheimer’s disease.
  36. El-Assy AM, Amer HM, Ibrahim HM, Mohamed MA. A novel CNN architecture for accurate early detection and classification of Alzheimer’s disease using MRI data. Sci Rep. 2024;14(1):3463.
  37. Paul R, Hossain A, Islam MT, Hassan Melon MM, Hussen M. Integrating genomic data with AI algorithms to optimize personalized drug therapy: A pilot study. Libr Prog Libr Sci Inf Technol Comput. 2024;44(3).
  38. Hong Y, Song Y, Wang W, Shi J, Chen X. Mitochondrial DNA editing: Key to the treatment of neurodegenerative diseases. Genes Dis. 2024:101437.
  39. Elly B. Accelerated nanoparticle-biosystem interactions modeling using artificial intelligence and GPU computing. Comput Biol Med. 2023;157:106735..
  40. Singh AV, Varma M, Rai M, Pratap Singh S, Bansod G, Laux P, et al. Advancing predictive risk assessment of chemicals via integrating machine learning, computational modeling, and chemical/nano-quantitative structure-activity relationship approaches. Adv Intell Syst. 2024;6(4):2300366.
  41. Li YH, Li YL, Wei MY, Li GY. Innovation and challenges of artificial intelligence technology in personalized healthcare. Sci Rep. 2024;14(1):18994.
  42. Williamson SM, Prybutok V. Balancing privacy and progress: A review of privacy challenges, systemic oversight, and patient perceptions in AI-driven healthcare. Appl Sci. 2024;14(2):675.
  43. Arreche O, Guntur TR, Roberts JW, Abdallah M. E-XAI: Evaluating black-box explainable AI frameworks for network intrusion detection. IEEE Access. 2024;12:23954–88.
  44. Visaggi P, Del Corso G, Svizzero FB, Ghisa M, Bardelli S, Venturini A, et al. Artificial intelligence tools for the diagnosis of eosinophilic esophagitis in adults reporting dysphagia: Development, external validation, and software creation for point-of-care use. J Allergy Clin Immunol Pract. 2024;12(4):1008–16.
  45. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. In: Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. 2024. p.1461–98.
  46. Hassan M, Kushniruk A, Borycki E. Barriers to and facilitators of artificial intelligence adoption in health care: Scoping review. JMIR Hum Factors. 2024;11:e48633.
  47. Nair M, Svedberg P, Larsson I, Nygren JM. A comprehensive overview of barriers and strategies for AI implementation in healthcare: Mixed-method design. PLoS One. 2024;19(8):e0305949.
Regular Issue Subscription Review Article
Volume 16
Issue 01
Received 30/11/2025
Accepted 01/12/2025
Published 19/03/2026
Publication Time 109 Days
4

Login


My IP

PlumX Metrics